The European Rare Kidney Disease Reference Network


Journal Watch

Thrombotic microangiopathies

Small-molecule factor B inhibitor for the treatment of complement-mediated diseases.
Author(s): Schubart A, Anderson K, Mainolfi N, Sellner H, Ehara T, Adams CM, Mac Sweeney A, Liao SM, Crowley M, Littlewood-Evans A, Sarret S, Wieczorek G, Perrot L, Dubost V, Flandre T, Zhang Y, Smith RJH, Risitano AM, Karki RG, Zhang C, Valeur E, Sirockin F, Gerhartz B, Erbel P, Hughes N, Smith TM, Cumin F, Argikar UA, Haraldsson B, Mogi M, Sedrani R, Wiesmann C, Jaffee B, Maibaum J, Flohr S, Harrison R, Eder J
Source: Proc Natl Acad Sci U S A 2019 Mar 29;
Publication date: 2019-03-29
Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors.
Author(s): Le Clech A, Simon-Tillaux N, Provôt F, Delmas Y, Vieira-Martins P, Limou S, Halimi JM, Le Quintrec M, Lebourg L, Grangé S, Karras A, Ribes D, Jourde-Chiche N, Rondeau E, Frémeaux-Bacchi V, Fakhouri F
Source: Kidney Int 2019 Mar 15;
Publication date: 2019-03-15
Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation.
Author(s): Ueda Y, Miwa T, Ito D, Kim H, Sato S, Gullipalli D, Zhou L, Golla M, Song D, Dunaief JL, Palmer MB, Song WC
Source: Kidney Int 2019 Feb 27;
Publication date: 2019-02-27
Atypical haemolytic uraemic syndrome in the eculizumab era: presentation, response to treatment and evaluation of an eculizumab withdrawal strategy.
Author(s): Neave L, Gale DP, Cheesman S, Shah R, Scully M
Source: Br J Haematol 2019 Mar 27;
Publication date: 2019-03-27
+ Show 42 more...